Email This Article
Headlines & Perspectives
Verdict Boosts Amgen
By
Elizabeth Trotta
10/23/07 - 11:47 AM EDT
Roche won't be allowed to sell Mircera, its rival medicine to Amgen's Aranesp and Epogen, in the U.S.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,501.05 | 1,114.11 | 2,212.10 | 35.46 |
Oil *
71.84
|
|
UP
29.55
|
UP
7.70
|
UP
21.79
|
UP
0.06
|
10 Yr
3.55%
SPDR Gold
110.24
|
|
+0.28%
|
+0.70%
|
+0.99%
|
+0.17%
|
Data delayed 20 minutes |


Connect with TheStreet